resist
defin
either
failur
achiev
initi
complet
remiss
cr
relaps
cr
remain
princip
problem
adult
acut
myeloid
leukemia
aml
wide
appreci
likelihood
resist
therapi
differ
significantli
individu
eg
complet
remiss
cr
rate
follow
initi
chemotherapi
patient
abil
accur
forecast
resist
would
consider
signific
manag
aml
evalu
new
drug
specif
better
abil
predict
resist
standard
therapi
less
need
might
random
patient
therapi
investig
therapi
lack
need
random
would
address
seldom
discuss
real
ethic
conundrum
physician
care
aml
patient
gener
enthusiast
random
patient
featur
associ
resist
older
age
complex
cytogenet
secondari
aml
etc
standard
therapi
will
believ
abil
predict
resist
standard
therapi
fair
thu
random
necessari
properli
evalu
new
therapi
therefor
set
test
belief
quantifi
current
abil
predict
resist
may
import
distinguish
associ
predict
well
known
clinic
cytogenet
molecular
characterist
strongli
associ
quantifi
odd
ratio
hazard
ratio
pvalu
standard
measur
valuabl
tradit
measur
give
insight
degre
given
prognost
factor
improv
abil
predict
outcom
individu
patient
provinc
measur
predict
area
receiv
oper
curv
auc
conceptu
closer
auc
less
need
might
random
patient
standard
therapi
ie
therapi
outcom
predict
novel
therapi
herein
use
auc
conjunct
clinic
cytogenet
molecular
data
adult
newli
diagnos
aml
treat
trial
conduct
uk
medic
research
counciln
cancer
research
institut
mrcncri
dutchbelgian
cooper
trial
group
hematologyoncolog
swiss
group
clinic
cancer
research
hovonsakk
us
cooper
group
swog
md
anderson
cancer
center
mda
quantifi
abil
predict
therapeut
resist
use
uni
multiparamet
model
trial
analyz
primarili
enrol
adult
newli
diagnos
aml
acut
promyelocyt
leukemia
base
classif
specif
use
data
patient
receiv
curativeint
treatment
mrcncri
trial
hovonsakk
trial
swog
trial
receiv
treatment
variou
protocol
mda
expect
intergroup
differ
regard
type
therapeut
regimen
use
exampl
induct
treatment
gener
contain
cytarabin
daunorubicin
idarubicin
therapi
mda
often
includ
cytarabin
mrcncri
typic
rather
day
cytarabin
use
moreov
hovonsakk
post
remiss
therapi
often
includ
amsacrin
institut
review
board
particip
institut
approv
protocol
patient
treat
accord
declar
helsinki
earli
death
treatmentrel
mortal
trm
defin
death
within
day
initi
studi
registr
exact
date
initi
therapi
unknown
complet
remiss
cr
convent
defin
achiev
morpholog
leukemiafre
state
bone
marrow
blast
absenc
extramedullari
diseas
recoveri
peripher
blood
count
absolut
neutrophil
count
platelet
count
overal
surviv
os
defin
time
initi
therapi
studi
registr
date
initi
therapi
unknown
death
censor
day
patient
last
known
aliv
patient
achiev
cr
relapsefre
surviv
rf
defin
time
achiev
remiss
relaps
death
caus
patient
known
relaps
die
censor
last
followup
rather
settl
singl
arbitrari
criterion
defin
therapeut
resist
use
sever
criteria
resist
failur
attain
cr
despit
surviv
least
day
begin
induct
therapi
primari
refractori
b
primari
refractori
rf
month
c
primari
refractori
rf
month
primari
refractori
rf
month
os
rf
estim
use
kaplanmei
chisquar
test
kruskalw
test
use
assess
differ
categor
variabl
median
valu
numer
variabl
across
categori
respect
use
logist
regress
analys
assess
relationship
individu
covari
variou
work
definit
therapeut
resist
use
auc
quantifi
model
abil
predict
therapeut
resist
approach
auc
indic
perfect
predict
auc
indic
predict
natur
wonder
whether
chang
auc
observ
exampl
statist
signific
howev
rule
permit
one
say
whether
given
chang
auc
statist
signific
rather
depend
effect
size
patient
number
given
larg
number
model
evalu
even
larger
number
pairwis
comparison
consid
import
focu
magnitud
auc
valu
chang
valu
rather
statist
signific
use
commonli
accept
criteria
auc
indic
poor
fair
good
predict
abil
altern
way
interpret
auc
proport
patient
correctli
rank
exampl
model
auc
correctli
rank
patient
higher
risk
larger
risk
score
time
time
model
incorrectli
give
person
higher
risk
lower
risk
score
person
lower
risk
interpret
auc
linear
model
auc
improv
model
auc
follow
pretreat
covari
use
regress
model
age
studi
registr
perform
statu
gender
white
blood
cell
wbc
count
platelet
count
bone
marrow
blast
percentag
diseas
type
primari
vs
secondari
cytogenet
risk
well
mutat
statu
miss
cytogenet
risk
account
separ
categori
rel
import
predictor
multivari
regress
model
evalu
valu
partial
wald
chisquar
statist
minu
predictor
degre
freedom
bootstrap
demonstr
effici
method
assess
intern
model
accuraci
crossvalid
split
data
two
use
estim
biascorrect
valu
auc
report
auc
bootstrapbia
correct
analys
perform
use
r
http
wwwrprojectorg
dataset
includ
predominantli
adult
newli
diagnos
aml
treat
mrcncri
hovonsakk
swog
protocol
given
treatment
mda
pretreat
inform
age
gender
perform
statu
wbc
platelet
count
bone
marrow
blast
percentag
secondari
aml
mutat
statu
outcom
data
avail
better
assess
resist
follow
initi
chemotherapi
exclud
patient
die
within
day
initi
induct
chemotherapi
lost
followup
time
leav
patient
median
age
year
treatment
site
mrcncri
hovonsakk
swog
mda
patient
baselin
characterist
present
tabl
summar
tabl
cr
initi
cours
induct
chemotherapi
achiev
patient
wherea
primari
refractori
patient
suffici
followup
time
either
primari
refractori
rf
month
less
cr
achiev
patient
suffici
followup
time
either
primari
refractori
rf
month
less
cr
achiev
patient
suffici
followup
time
primari
refractori
rf
month
less
cr
achiev
patient
primari
refractori
aml
wide
consid
exhibit
highest
degre
resist
surprisingli
serv
data
reliabl
check
age
p
perform
statu
wbc
p
secondari
diseas
p
cytogenet
risk
favor
intermedi
vs
advers
p
comparison
mutat
well
statu
vs
p
comparison
independ
associ
primari
refractori
induct
chemotherapi
consid
patient
tabl
shown
figur
age
import
individu
covari
predict
failur
achiev
cr
follow
cytogenet
risk
statu
indic
valu
partial
wald
chisquar
statist
despit
strong
associ
covari
primari
refractori
aml
auc
valid
bootstrapadjust
suggest
predict
abil
less
impress
specif
univari
model
auc
valu
age
cytogenet
risk
mutat
statu
bootstrapcorrect
multivari
model
incorpor
covari
age
perform
statu
wbc
platelet
count
bone
marrow
blast
percentag
gender
diseas
type
primari
vs
secondari
cytogenet
risk
well
mutat
statu
yield
auc
despit
strong
associ
primari
refractori
aml
remov
model
statist
signific
effect
auc
decreas
auc
slightli
see
supplement
figur
auc
vari
consider
among
treatment
site
withwithout
mutat
inform
perform
sever
addit
analys
predict
primari
refractori
aml
first
inform
mutat
statu
current
thought
clinic
help
guid
decisionmak
patient
cytogenet
normal
aml
restrict
analysi
patient
normal
karyotyp
diagnosi
multivari
model
without
inform
combin
dataset
yield
auc
respect
auc
individu
treatment
site
inclus
without
inclus
thu
auc
valu
higher
valu
unrestrict
dataset
present
individu
cohort
inclus
mutat
inform
improv
predict
perform
model
compar
model
incorpor
cytogenet
group
us
select
induct
chemotherapi
newli
diagnos
aml
commonli
made
cytogenet
mutat
inform
avail
second
addit
analysi
aim
evalu
auc
circumst
built
multivari
model
without
inclus
molecular
cytogenet
inform
accuraci
model
significantli
lower
indic
auc
obtain
entir
patient
cohort
auc
individu
treatment
site
rang
third
examin
whether
predict
accuraci
improv
focus
rel
homogen
subset
howev
analysi
limit
patient
de
novo
aml
yield
bootstrapcorrect
auc
multivari
model
without
inform
ie
lower
entir
studi
cohort
similarli
restrict
attent
separ
patient
age
year
younger
older
year
auc
higher
entir
studi
cohort
younger
patient
older
patient
multivari
model
without
inform
respect
final
recent
studi
indic
mani
patient
achiev
cr
ident
second
cours
chemotherapi
first
cours
restrict
analysi
patient
declar
primari
refractori
cours
chemotherapi
inform
receipt
vs
cycl
induct
therapi
avail
swog
cohort
patient
fail
first
cours
induct
chemotherapi
receiv
reinduct
protocol
subset
analysi
remain
patient
bootstrapcorrect
auc
multivari
model
without
inform
ie
valu
lower
entir
swog
cohort
respect
assess
whether
result
similar
use
criteria
resist
perform
addit
analys
consid
resist
primari
refractori
aml
also
rf
month
date
first
cr
shown
figur
rel
import
individu
covari
chang
slightli
criterion
resist
alter
mutat
statu
cytogenet
risk
gradual
replac
age
import
individu
covari
time
predict
attempt
increas
predict
abil
decreas
specif
analyz
entir
studi
cohort
auc
model
predict
primari
refractori
diseas
rf
month
withwithout
inclus
mutat
data
tabl
supplement
tabl
tabl
supplement
tabl
tabl
supplement
tabl
respect
vs
consid
primari
refractori
aml
alon
although
previou
data
suggest
day
reason
criterion
distinguish
patient
fail
therapi
plausibl
patient
die
day
suffici
aml
present
death
would
consid
resist
live
beyond
day
henc
exclus
patient
die
day
might
affect
conclus
therefor
perform
addit
analys
includ
patient
die
day
lost
followup
time
summar
tabl
conclus
essenti
unaffect
inclus
patient
auc
model
predict
primari
refractori
diseas
rf
month
respect
mutat
data
includ
one
might
suspect
abil
predict
resist
higher
patient
highrisk
convers
favor
cytogenet
test
possibl
perform
separ
analys
resist
favorablerisk
intermediaterisk
unfavorablerisk
cytogenet
group
howev
evid
auc
differ
differ
cytogenet
risk
group
regardless
whether
data
includ
even
unfavorablerisk
group
auc
remain
rel
low
model
predict
primari
refractori
diseas
rf
month
aml
patient
fail
cure
primarili
resist
therapi
domin
role
resist
note
previous
patient
well
analys
patient
cohort
consist
previou
data
patient
experienc
trm
die
cr
accur
method
predict
resist
standard
therapi
need
physician
reliabl
advis
aml
patient
specif
abil
predict
resist
suffici
high
would
difficult
recommend
standard
therapi
patient
similarli
difficult
recommend
investig
therapi
other
experi
suggest
recommend
commonli
made
howev
made
absenc
quantit
measur
predict
abil
perhap
surprisingli
confirm
age
perform
statu
wbc
secondari
diseas
cytogenet
risk
mutat
statu
strongli
independ
associ
p
resist
result
suggest
abil
predict
resist
much
less
impress
inde
use
standard
criteria
relat
auc
predict
abil
abil
fair
littl
improv
inclus
data
aberr
true
attent
restrict
homogen
subset
younger
patient
de
novo
aml
find
denot
fair
abil
predict
cr
reminisc
recent
studi
krug
et
al
observ
similar
auc
multivari
model
studi
cohort
although
definit
primari
refractori
aml
slightli
clinician
might
understand
feel
even
fair
predict
abil
justifi
recommend
patient
receiv
standard
therapi
other
investig
therapi
other
might
feel
rel
low
auc
resist
support
random
standard
investig
therapi
thu
studi
provid
rational
continu
random
best
mean
accur
evalu
compar
efficaci
new
standard
therapi
resist
undoubtedli
difficult
predict
aml
extraordinarili
complex
heterogen
diseas
whose
divers
partial
captur
clinic
paramet
cytogenet
data
inform
aberr
covari
examin
mutat
mani
addit
gene
may
carri
prognost
degre
may
depend
coexist
alter
would
therefor
interest
assess
degre
auc
could
improv
incorpor
data
addit
genet
molecular
analys
pretreat
assay
test
aml
signal
pathway
function
moreov
differ
aml
subclon
may
exhibit
differenti
chemotherapi
sensit
resist
reflect
emerg
subclon
whose
import
determin
initi
emerg
clone
like
make
difficult
forecast
resist
period
forecast
attempt
increas
increas
difficulti
seen
move
predict
primari
resist
predict
primari
resist
rf
contrast
previou
effort
predict
death
within
day
begin
chemotherapi
integr
posttreat
data
eg
earli
diseas
clearanc
case
primari
refractori
aml
achiev
cr
vs
crpcri
assess
minim
residu
case
rf
may
improv
predict
resist
data
deriv
wellannot
patient
treat
contemporari
aml
regimen
sever
limit
need
acknowledg
first
result
may
appli
newli
diagnos
aml
treat
intens
regimen
may
influenc
allogen
transplant
limit
inform
second
rather
harmon
cytogenet
risk
categori
across
studi
cohort
use
cooper
studi
group
separ
classif
howev
recod
swog
patient
cohort
refin
mrcncri
slightli
chang
auc
multivari
predict
model
chang
addit
categor
patient
monosom
separ
risk
entiti
improv
auc
third
distinguish
relaps
death
cr
event
contribut
short
rf
criterion
resist
analys
patient
die
cr
necessarili
resist
previou
studi
indic
patient
die
cr
much
similar
patient
relaps
remain
aliv
fourth
use
independ
dataset
obtain
unbias
estim
auc
model
present
paper
howev
goal
paper
gener
one
predict
model
rather
aim
investig
predict
abil
model
chang
cytogenet
molecular
inform
incorpor
model
assess
whether
similar
trend
across
separ
cohort
purpos
valid
via
provid
use
approach
assess
intern
model
accuraci
note
experi
suggest
model
perform
well
independ
dataset
dataset
use
deriv
thu
use
anoth
dataset
unlik
chang
fundament
conclus
ie
use
current
prognost
factor
guid
treatment
decis
like
overestim
support
separ
analys
data
swog
mda
hovon
mrc
conclus
abil
predict
therapeut
resist
base
routin
avail
clinic
covari
even
inclus
commonli
use
molecular
data
rel
limit
find
appear
signific
clinic
consequ
infrequ
multivari
analysi
use
examin
whether
account
covari
cytogenet
statu
new
treatment
superior
older
one
howev
predict
abil
covari
limit
result
indic
relianc
histor
control
assess
new
treatment
problemat
thu
result
emphas
continu
import
random
treatment
assign
test
new
drug
aml
